Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 17/20 | 0.51 |
| ▸ | CYBB | P04839 | 10/20 | 0.51 |
| ▸ | NOX5 | Q96PH1 | 9/20 | 0.48 |
| ▸ | NOX1 | Q9Y5S8 | 9/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931691 | 1.00 | NOX4 (0.51) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL29523126 | 0.94 | NOX4 (0.51) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL14931684 | 0.94 | NOX4 (0.51) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL29523385 | 0.92 | NOX4 (0.51) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL14931723 | 0.92 | NOX4 (0.51) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL29523450 | 0.91 | NOX4 (0.53) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL14931690 | 0.91 | NOX4 (0.53) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL29523655 | 0.88 | NOX4 (0.54) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL14931680 | 0.88 | NOX4 (0.54) | NOX4CYBBNOX5NOX1GABRA1 | |
| SCHEMBL14931671 | 0.87 | NOX4 (0.51) | NOX4CYBBNOX5NOX1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | claimed |
| CN-119212698-A | NOX inhibitors for the treatment of Albert syndrome | 瑞士商卡利迪塔斯疗法瑞士股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| CN-119212698-A | NOX inhibitors for the treatment of Albert syndrome | 瑞士商卡利迪塔斯疗法瑞士股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-117881403-A | Thionucleosides as antiviral agents | 爱莫里大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117769427-A | Modified nucleosides and nucleotide analogues as antiviral agents for coronaviruses and other viruses | 埃默里大学 | 2024-03-26 | — | — | CN | disclosed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319764-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217153-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022217154-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2022-09-01 | — | — | US | disclosed |
| EP-3980400-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | Emory University (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114026067-A | Peptide mimetics for the treatment of coronavirus and picornavirus infections | 埃默里大学 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | NOX4 4661/4885CYBB 4765/4885NOX5 4599/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | NOX4 4650/4885CYBB 4793/4885NOX5 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.